Baxter International Inc.

NYSE:BAX

Medical - Instruments & Supplies

Healthcare
$26.16 -5.23%

-$1.07 today

Market cap
$13.53B
Beta
0.64
P/E (TTM)
-9.1
EPS (TTM)
-$2.13
Dividend yield
1.03%
52W Low $15.73High $31.76

Volume 4.01M

Average 7.62M

BAX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Baxter International Inc.NYSE: BAX

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows, but more slowly than its trailing trend

Q2 FY2026 cost of revenue of $1.93B rose 6.0% year over year, behind the +13.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Cost of revenue amounted to 69.9% of revenue in FY2025, up 7.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.0% toward the trailing-twelve-month pace of +13.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.93B+6.5% QoQ
Last fiscal yearDec 2025
$7.87B+18.2% YoY
LTMJun 2026
$8.02B+13.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.0%——
1 year+18.2%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
7.87B USD
Year-over-year change
+18.2%
4-year CAGR
+1.4%

Cost of Revenue vs competitors

How BAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.9% is the highest of 5, against a peer median of -3.6%.
  • Cost of revenue amounts to 69.9% of revenue for BAX, versus a peer median of 65.7%.
BAX Competitors
Cost of Revenue for BAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€14.31B EUR-2.7%+0.2%73.6%
DVADaVita Inc.LTM Jun 2026$9.66B USD+8.8%+6.7%69.0%
BAXBaxter International Inc.LTM Jun 2026$8.02B USD+13.9%+6.5%69.9%
ICUIICU Medical, Inc.LTM Jun 2026$1.35B USD-11.4%-3.8%62.4%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$61.59M USD-4.5%+8.6%43.3%
Peer median (excluding BAX) —-3.6%+3.4%65.7%

Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.15B10.06B10.36B10.64B11.24B
Cost of Revenue7.43B6.51B6.21B6.65B7.87B
Gross Profit4.72B3.55B4.15B3.98B3.38B
Gross Margin38.9%35.3%40.1%37.5%30.1%
Research & Development531M450M518M590M518M
Selling, General & Admin2.85B3.1B2.95B2.97B2.89B
Operating Expenses3.37B6.39B3.44B3.97B3.69B
Depreciation & Amortization867M1.07B984M997M981M
EBITDA2.19B(1.76B)1.73B1.12B766M
EBITDA Margin18.0%-17.5%16.7%10.5%6.8%
Operating Income1.35B(2.85B)707M14M(308M)
Operating Margin11.1%-28.3%6.8%0.1%-2.7%
Interest Income14M19M69M67M52M
Interest Expense207M413M508M408M290M
Other Income / Expenses(234M)(403M)(465M)(303M)(197M)
Income Before Tax1.12B(3.25B)242M(289M)(505M)
Pre-Tax Margin9.2%-32.3%2.3%-2.7%-4.5%
Income Tax Expense83M(135M)61M37M395M
Net Income1.28B(2.43B)2.66B(649M)(957M)
Net Margin10.6%-24.2%25.6%-6.1%-8.5%
EPS (Basic)2.56(4.83)5.25(1.27)(1.75)
EPS (Diluted)2.53(4.83)5.23(1.27)(1.75)
Weighted Avg Shares502M504M506M510M513M
Weighted Avg Shares (Diluted)508M504M506M510M513M

Baxter International Inc.

NYSE:BAX

Intrinsic Alpha fair value

Locked

Current Price

$26.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.